Skip to main content
. 2020 May 1;10(5):1467–1476.

Figure 3.

Figure 3

The probability of developing at least grade 2 HFS between the two groups. The data were stratified according to treatment, and compared with the sorafenib group, the SoraCele group had a significantly lower probability of developing at least grade 2 HFS, with a HR of 0.384 (P = 0.002).